BidaskClub downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research note published on Tuesday morning.
Several other research analysts have also recently weighed in on the company. HC Wainwright assumed coverage on Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a buy rating and a $21.00 price objective on the stock. Needham & Company LLC upped their price target on Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a buy rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. Piper Jaffray Companies reaffirmed a buy rating and set a $24.00 price target on shares of Collegium Pharmaceutical in a research report on Thursday, December 7th. Jefferies Group upped their price target on Collegium Pharmaceutical to $27.00 and gave the company a buy rating in a research report on Tuesday, December 5th. Finally, Zacks Investment Research raised Collegium Pharmaceutical from a hold rating to a buy rating and set a $16.00 price target on the stock in a research report on Monday, November 13th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. Collegium Pharmaceutical currently has an average rating of Buy and an average target price of $23.33.
Collegium Pharmaceutical (NASDAQ COLL) opened at $20.02 on Tuesday. Collegium Pharmaceutical has a 1 year low of $7.37 and a 1 year high of $21.38.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The business had revenue of $11.95 million for the quarter, compared to analysts’ expectations of $5.31 million. During the same quarter in the previous year, the firm earned ($1.13) earnings per share. The business’s revenue was up 2814.6% on a year-over-year basis. equities analysts predict that Collegium Pharmaceutical will post -2.52 EPS for the current fiscal year.
In related news, CEO Michael Thomas Heffernan sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $15.53, for a total transaction of $776,500.00. Following the sale, the chief executive officer now directly owns 558,987 shares in the company, valued at approximately $8,681,068.11. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Alison B. Fleming sold 6,928 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $19.07, for a total value of $132,116.96. Following the sale, the insider now owns 32,651 shares in the company, valued at $622,654.57. The disclosure for this sale can be found here. Insiders have sold a total of 1,065,558 shares of company stock worth $18,396,477 in the last ninety days. Insiders own 25.76% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. Pura Vida Investments LLC bought a new stake in shares of Collegium Pharmaceutical during the 3rd quarter valued at $1,229,000. Wells Fargo & Company MN raised its stake in shares of Collegium Pharmaceutical by 12.8% during the 3rd quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock valued at $475,000 after purchasing an additional 5,136 shares during the period. Citadel Advisors LLC raised its stake in shares of Collegium Pharmaceutical by 773.8% during the 3rd quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock valued at $5,707,000 after purchasing an additional 481,771 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Collegium Pharmaceutical during the 3rd quarter valued at $192,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Collegium Pharmaceutical during the 3rd quarter valued at $201,000. Institutional investors own 79.98% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Collegium Pharmaceutical (COLL) Downgraded to “Buy” at BidaskClub” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://transcriptdaily.com/2018/01/13/collegium-pharmaceutical-coll-downgraded-to-buy-at-bidaskclub.html.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.